OBJECTIVE: To describe a novel mutation (K239N) in the PSEN1 associated with familial Alzheimer's disease (AD). METHODS AND RESULTS: The proband was a man who developed cognitive decline with marked behavioural abnormalities at age 57. At age 70, he was admitted into a psychiatric facility because of aggressiveness and a suicide attempt. Family history was consistent with autosomal dominant AD. One of the two other family members studied presented also with prominent behavioural symptoms at age 42 and has also been forced into a psychiatric facility because of aggressiveness at age 56. The remainder patient has presented a prototypical AD, but starting at age 71. Direct sequencing of PSEN1 in the three living affected members disclosed a heterozygous G to C transition in exon 7 of PSEN1 leading to the K239N mutation. CONCLUSION: The K239N mutation is associated with autosomal dominant AD with a wide range of age of onset and incomplete penetrance at the age of 65, prominent behavioural features and slow progression.
OBJECTIVE: To describe a novel mutation (K239N) in the PSEN1 associated with familial Alzheimer's disease (AD). METHODS AND RESULTS: The proband was a man who developed cognitive decline with marked behavioural abnormalities at age 57. At age 70, he was admitted into a psychiatric facility because of aggressiveness and a suicide attempt. Family history was consistent with autosomal dominant AD. One of the two other family members studied presented also with prominent behavioural symptoms at age 42 and has also been forced into a psychiatric facility because of aggressiveness at age 56. The remainder patient has presented a prototypical AD, but starting at age 71. Direct sequencing of PSEN1 in the three living affected members disclosed a heterozygous G to C transition in exon 7 of PSEN1 leading to the K239N mutation. CONCLUSION: The K239N mutation is associated with autosomal dominant AD with a wide range of age of onset and incomplete penetrance at the age of 65, prominent behavioural features and slow progression.
Authors: Sigrun Roeber; Felix Müller-Sarnowski; Julia Kress; Dieter Edbauer; Tanja Kuhlmann; Frank Tüttelmann; Christoph Schindler; Pia Winter; Thomas Arzberger; Ulrich Müller; Adrian Danek; Hans A Kretzschmar Journal: J Neural Transm (Vienna) Date: 2015-09-08 Impact factor: 3.575
Authors: Simon Kang Seng Ting; Tammie Benzinger; Vladimir Kepe; Anne Fagan; Giovanni Coppola; Verna Porter; Silva Hecimovic; Suma Chakraverty; Ana Isabel Alvarez-Retuerto; Alison Goate; John M Ringman Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Steffan K Soosman; Nelly Joseph-Mathurin; Meredith N Braskie; Yvette M Bordelon; David Wharton; Maria Casado; Giovanni Coppola; Holly McCallum; Marc Nuwer; Pedro Coutin-Churchman; Liana G Apostolova; Tammie Benzinger; John M Ringman Journal: Neurobiol Aging Date: 2016-08-08 Impact factor: 4.673
Authors: Carlos Cruchaga; Gabe Haller; Sumitra Chakraverty; Kevin Mayo; Francesco L M Vallania; Robi D Mitra; Kelley Faber; Jennifer Williamson; Tom Bird; Ramon Diaz-Arrastia; Tatiana M Foroud; Bradley F Boeve; Neill R Graff-Radford; Pamela St Jean; Michael Lawson; Margaret G Ehm; Richard Mayeux; Alison M Goate Journal: PLoS One Date: 2012-02-01 Impact factor: 3.240
Authors: Steinunn Thordardottir; Elena Rodriguez-Vieitez; Ove Almkvist; Daniel Ferreira; Laure Saint-Aubert; Anne Kinhult-Ståhlbom; Håkan Thonberg; Michael Schöll; Eric Westman; Anders Wall; Maria Eriksdotter; Henrik Zetterberg; Kaj Blennow; Agneta Nordberg; Caroline Graff Journal: Alzheimers Res Ther Date: 2018-05-10 Impact factor: 6.982